|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||105.65 - 106.05|
|52 Week Range||92.58 - 106.43|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.06%|
Although value has been out-of-favor relative to growth in recent years, more cautious advisors are increasingly looking towards value. We turn to our MoneyShow.com contributors for some top ETF ideas ...
Vanguard Group, best known for pioneering index investing, said Tuesday that it intends to debut six quant stock exchange-traded funds in the new year.
In 3Q17, Merck’s (MRK) Keytruda generated revenue of ~$1.0 billion, compared with $346 million in 3Q16. In 3Q17, Keytruda witnessed ~19% growth QoQ (quarter-over-quarter). Sales volume growth in the US ...
This has been another year of brisk new product launches from the exchange-traded funds industry as hundreds of new funds have come to market. As is often the case, some new ETFs take awhile to attract ...
ETF adoption has rapidly accelerated in recent years, with many investors steering to cheap ETFs to potentially bolster long-term investment returns. There are 2,040 U.S.-listed ETFs on the market with ...
Goldman Sachs Asset Management is ramping up a price war with the pending launch of a new "smart-beta" exchange-traded fund with an expense ratio as low as 0.09% (or 9 basis points) -- a level even lower than some passive index funds, says Moody's Investors Service. Analyst Stephen Tu writes: GSAM’s move expands the ETF price war beyond plain vanilla ETFs into smart-beta ETFs, implying that the industry’s higher pricing assumptions for smart-beta products will not hold.
Zimmer Biomet registered net sales of $1.95 billion, exceeding the analysts’ estimate, and saw year-over-year sales growth of around 1.1%.
A prominent theme among U.S. equity exchange traded funds this year is the laggard status of the value factor. Just look at the Vanguard Value ETF (NYSEArca: VTV). VTV, the largest value ETF by assets, ...
In 2Q17, Merck’s (MRK) Gardasil/Gardasil 9 generated revenues of ~$469 million, which reflected ~19% growth year-over-year and ~12% growth quarter-over-quarter.
On July 20, 2017, Abbott Laboratories (ABT) released its 2Q17 earnings. That day, ABT stock rose more than 4.0% from its closing price of $49.40 on July 19, 2017.